logo

Theseus Pharmaceuticals, Inc. (THRX)



Trade THRX now with
  Date
  Headline
5/12/2022 7:23:14 AM Theseus Pharma Q1 Net Loss $10.5 Mln Vs Loss Of $4.5 Mln Last Year
3/10/2022 4:38:52 PM Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) FY22 Estimate To -1.11 From -1.42
3/10/2022 4:38:31 PM Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q4 22 Estimate To -0.32 From -0.40
3/10/2022 4:38:17 PM Wedbush Is Increasing Theseus Pharmaceuticals, Inc. (THRX) Q3 22 Estimate To -0.30 From -0.37
3/10/2022 4:37:57 PM Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q2 22 Estimate To -0.25 From -0.34
3/10/2022 4:37:44 PM Wedbush Is Raising Theseus Pharmaceuticals, Inc. (THRX) Q1 22 Estimate To -0.24 From -0.30
3/10/2022 4:37:02 PM Wedbush Reiterates Theseus Pharmaceuticals, Inc. (THRX) At Outperform With $24 Price Target
3/10/2022 7:24:30 AM Theseus Pharma Q4 Loss Widens To $8.7 Mln From $2.9 Mln Prior Year
2/2/2022 7:35:53 AM Theseus Gets FDA Orphan Drug Designation For THE-630 For Treatment Of Advanced Gastrointestinal Stromal Tumors
11/15/2021 7:13:53 AM Theseus Pharmaceuticals Q3 Net Loss Widens To $7.4 Mln From $1.4 Mln Last Year
11/1/2021 8:24:40 AM Wedbush Starts THERAVANCE, INC. (THRX) At Outperform With $24 Price Target
10/6/2021 10:37:01 PM Theseus Pharma Prices IPO Of 10.00 Mln Shares At $16.00/shr
8/6/2014 5:04:14 PM THERAVANCE, INC. (THRX) Declares $ 0.25 Dividend for Q3 14, Record Date 8/28/2014
8/1/2012 8:09:49 AM Robert W. Baird Is Raising THERAVANCE, INC. (THRX) FY12 Estimate To -0.30 From -0.33
5/1/2012 7:56:44 AM Robert W. Baird Is Increasing THERAVANCE, INC. (THRX) FY 13 Estimate To -1.11 From -1.26
5/1/2012 7:56:25 AM Robert W. Baird Is Lowering THERAVANCE, INC. (THRX) FY 12 Estimate To -0.33 From -0.32
2/10/2012 7:59:53 AM Robert W. Baird Is Increasing THERAVANCE, INC. (THRX) FY 12 Estimate To -0.32 From -1.32